Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00050674 · ClinicalTrials.gov registry record · Phase 2

Docetaxel and Gemcitabine With Filgrastim-SD/01 Support in Patients With Advanced Non-Small Cell Lung Carcinoma

A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Schwartzberg, Lee, M.D..

Completed
Registry status
Phase 2
Development phase
40
Enrollment target
2
Study locations

NCT00050674: Completed Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Schwartzberg, Lee, M.D..

NCT00050674 is a Phase 2 study of Non-Small Cell Lung Cancer that has completed, run by Schwartzberg, Lee, M.D.. The registered enrollment target is 40 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00050674, a Phase 2 study of Non-Small Cell Lung Cancer, has completed, sponsored by Schwartzberg, Lee, M.D..

COMPLETED
Registry status
Phase 2
Development phase
40 participants
Enrollment target
2
Study locations

Study Summary

Determine whether patients have a decreased incidence of grade 3 and grade 4 neutropenia when Filgrastim-SD/01 is given with docetaxel and gemcitabine in patients with advanced non-small cell lung cancer.

Conditions Studied

Non-Small Cell Lung Cancer

Interventions

  • DRUG Filgrastim-SD/01

Study Locations (2)

Mississippi

  • The West Clinic, PC - Southaven

Tennessee

  • The West Clinic, PC - Memphis

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2001-11
Est. Completion 2007-02
Phase Phase 2
Schwartzberg, Lee, M.D.

1 total trials

What the finished NCT00050674 record still lists

NCT00050674 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (94% lower).

The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Filgrastim-SD/01 is the first listed.

NCT00050674 reports a single indexed study location in Mississippi, Tennessee.

Frequently Asked Questions

What is clinical trial NCT00050674 about?

NCT00050674 is a clinical study titled "Docetaxel and Gemcitabine With Filgrastim-SD/01 Support in Patients With Advanced Non-Small Cell Lung Carcinoma". Determine whether patients have a decreased incidence of grade 3 and grade 4 neutropenia when Filgrastim-SD/01 is given with docetaxel and gemcitabine in patients with advanced non-small cell lung cancer.

What is the current status of trial NCT00050674?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2001-11. Estimated completion is 2007-02.

What conditions does trial NCT00050674 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.

What interventions are being tested in trial NCT00050674?

The interventions under investigation include: Filgrastim-SD/01 (DRUG).

Who is sponsoring clinical trial NCT00050674?

This trial is sponsored by Schwartzberg, Lee, M.D., which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00050674 being conducted?

This trial has 2 study locations across Mississippi, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00050674's enrollment target sits among peer trials

40 360th of 454 higher than 87 of 454 other Non-Small Cell Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00050674, the US trial registry maintained by the National Library of Medicine. NCT00050674 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.